Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03799900 · ClinicalTrials.gov registry record · Phase 1
Assessment of Abuse Potential of Rapastinel in Humans
A Phase 1 study of Human Abuse Potential, sponsored by Naurex, Inc, an affiliate of Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT03799900: Completed Phase 1 study of Human Abuse Potential, sponsored by Naurex, Inc, an affiliate of Allergan.
NCT03799900 is a Phase 1 study of Human Abuse Potential that has completed, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 72 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03799900, a Phase 1 study of Human Abuse Potential, has completed, sponsored by Naurex, Inc, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational polydrug users.
Primary Outcome
The drug liking VAS measures the participant's liking for the drug and is scored from 0 to 100, with 0 reflecting "Strong disliking" and 100 reflecting "Strong liking".
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ketamine
- DRUG Rapastinel
Study Locations (1)
Kansas
- Vince and Associates Clinical Research Inc - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2019-03-29 |
| Phase | Phase 1 |
What the finished NCT03799900 record still lists
NCT03799900 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher).
The record links to 1 condition, with Human Abuse Potential appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03799900 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT03799900 about?
NCT03799900 is a clinical study titled "Assessment of Abuse Potential of Rapastinel in Humans". Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR antagonist that is a Schedule III dissociative anesthetic, and placebo in recreational polydrug users.
What is the current status of trial NCT03799900?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2018-11-01. Estimated completion is 2019-03-29.
What conditions does trial NCT03799900 study?
This clinical trial studies the following conditions: Human Abuse Potential.
What interventions are being tested in trial NCT03799900?
The interventions under investigation include: Placebo (DRUG), Ketamine (DRUG), Rapastinel (DRUG).
Who is sponsoring clinical trial NCT03799900?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03799900 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03799900's enrollment target sits among peer trials
72 736th of 2000 higher than 1,254 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI